New drug combo shows promise for Tough-to-Treat stomach cancer
NCT ID NCT03686488
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 33 times
Summary
This study tested a combination of two drugs, TAS 102 and ramucirumab, in 23 people with advanced stomach or gastroesophageal junction cancer that had stopped responding to prior treatments. The goal was to see if the combination was safe and could help patients live longer. The study was completed, and results focused on overall survival and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.